Clinical Trial Update: Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) [Phase 2]

View source ↗

Summary

Pfizer completed a Phase 2 trial (MIRNA) evaluating metabolic interventions for nonalcoholic steatohepatitis with liver fibrosis. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease
• Nonalcoholinesteatohepatitis with Liver Fibrosis

Snippet

Sponsor: Pfizer | Conditions: Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis With Liver Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2025-03-21